All News

Robert A. Figlin, MD, Spotlights Key Findings With Adjuvant Pembrolizumab in Resected Clear Cell RCC From ASCO 2021
June 23, 2021

CancerNetwork® sat down with Robert A. Figlin, MD, at the 2021 ASCO Annual Meeting to discuss the results of the KEYNOTE-564 trial with adjuvant pembrolizumab in patients with resected clear cell renal cell carcinoma.

Early-Onset Colorectal Study Shows Better Overall Survival for Patients Under 50
June 23, 2021

Individuals with an early-onset colorectal cancer diagnosis had a survival benefit versus those at later ages, especially for patients younger than 50 years old.

Pembrolizumab Combo Significantly Improved Survival for Persistent, Recurrent, or Metastatic Cervical Cancer
June 23, 2021

Merck’s press release announced positive data from the KEYNOTE-826 trial investigating pembrolizumab plus chemotherapy with or without bevacizumab for patients with cervical cancer.